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Background: More than half a million new items of biomedical research are generated every year and added to
Medline. How successful are we at applying this steady accumulation of scientific knowledge and so improving the
practice of medicine in the USA?
Discussion: The conventional wisdom is that the US healthcare system is plagued by serious cost, access, safety
and quality weaknesses. A comprehensive solution must involve the better translation of an abundance of clinical
research into improved clinical practice.
Yet the application of knowledge (i.e. technology) remains far less well funded and less visible than the generation,
synthesis and accumulation of knowledge (i.e. science), and the two are only weakly integrated. Worse, technology
is often seen merely as an adjunct to practice, e.g. electronic health records.
Several key changes are in order. A helpful first step lies in better understanding the distinction between science
and technology, and their complementary strengths and limitations. The absolute level of funding for technology
development must be increased as well as being more integrated with traditional science-based clinical research. In
such a mission-oriented federal funding strategy, the ties between basic science research and applied research
would be better emphasized and strengthened.
Summary: It bears repeating that only by applying the wealth of existing and future scientific knowledge can
healthcare delivery and patient care ever show significant improvement.Background
More than half a million new items of biomedical re-
search are generated every year and added to Medline.
How successful are we at applying this steady accumula-
tion of scientific knowledge and so improving the prac-
tice of medicine? The conventional wisdom is that the
US healthcare system is plagued by serious cost, [1] ac-
cess, [2] safety, [3] fairness, [4] and quality [5] weak-
nesses. In combination, these many weaknesses yield a
system which provides sub-optimal value [6,7].
A comprehensive solution must involve the more effi-
cient translation of an abundance of clinical research
into improved clinical practice [8,9]. Yet the application* Correspondence: huesch@usc.edu
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distribution, and reproduction in any mediumof knowledge (i.e. technology) still remains far less well
funded and less visible than the generation, accumula-
tion and synthesis of knowledge (i.e. science), [10] and
the two are only weakly integrated despite attempts to
spur translational research with large NIH Translation
awards [11]. Worse, technology is often seen merely as
an adjunct to practice, e.g. electronic health records. In
this paper we discuss these issues and suggest potential
solutions.Discussion
Funding for translation of research
The Agency for Healthcare Research and Quality
(AHRQ) is the lead federal agency sponsoring the appli-
cation of health services knowledge, but has a budget of
less than $400 million per year. Adding the various trans-
lational research budgets in the National Institutes of
Health (NIH) comes to less than $1 billion per year, with
a focus predominantly on therapeutics as opposed to
health services and care delivery. Despite unprecedentedCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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search,11 and a commitment of around $500 million per
year for the Clinical and Translational Science Awards,
[12,13] there is still no empirical evidence that clinical re-
search has actually become more efficient [14]. Given a
total of nearly $32 billion in funded research, [15] the
amount and proportion spent implementing medical
knowledge and improving care delivery may be too small.
Several key changes are in order. We argue that the
absolute level of funding for technology development
must be increased as well as being more integrated with
traditional science-based clinical research. In such a
more mission-oriented federal funding strategy, the ties
between basic science research and applied research
would be better emphasized and strengthened. A helpful
first step lies in better understanding the distinction be-
tween science and technology, and their complementary
strengths and limitations.
The distinction between science and technology
Science is generally considered the search for and con-
struction of theories about cause [16]. Science generates,
synthesizes and accumulates knowledge in one narrow
area; its models hold much else ‘fixed’. On the other
hand, technology is the search for and production of
theories about new processes. Technology is the applica-
tion of existing knowledge; its models allow most every-
thing to vary. Simply put, science is the ‘why’, while
technology is the ‘how’ of improvement.
Advances in scientific knowledge in medicine are well-
known and manifold and steady scientific progress will
continue to lead to incremental improvements in accumu-
lated knowledge. But only the appropriate and effective
application of technology, through successful modification
and application of existing knowledge, can realize the pro-
mised gains in cost, safety and efficacy.
In the health care domain, however, technology is best
known as an enabler of process standardization and
communication between providers [17]. The federal gov-
ernment’s Health Information Technology for Economic
and Clinical Health (HITECH) Act reflects this import-
ant strength of technology, and rightly seeks to improve
practice by significant technology investments.
The full potential of technology
Yet electronic health records and process control do
not capture the full potential of what technology can
offer. For example, by integrating existing knowledge
from behavioral science, organization science, engineer-
ing and clinical research and applying this in simulated
environments, technology can improve and redesign
existing care processes as well as engineer new ones.
More generally, technology allows researchers and stake-
holders to overcome the inherently complex, interactingand dynamic nature of healthcare systems [18]. It is diffi-
cult to grasp all the linkages and interactions between
humans, equipment, medical devices, care processes and
biological systems. Faced with the need to improve such
chaotic systems scientists simplify the problem and ab-
stract the clinical setting. Clinical research routinely and
deliberately seeks to hold many aspects of the problem
fixed, and attempts to estimate the positive impact
of making a small, isolated change in one component
(e.g. the maximum hours worked by a provider).
This approach of holding many factors constant, and
making small, incremental changes in a small number of
factors is described as local optimization. However, such
local optimization may hide the much larger impact of
global optimization: making a larger number of coordi-
nated changes to multiple components at once (e.g. the
configuration of a medical instrument, the training of a
provider and the mix of patients admitted to the
system).
To view this conceptually, consider a system’s per-
formance as being highly non-linearly impacted by two
factors. Here non-linearity signifies that the response of
a system to one factor changes both with the level of
that factor and the level of the other factor, and that
those responses vary in a complex way. One way to
visualize this is by taking a three dimensional coordinate
system. Plot the levels of the two factors in the two hori-
zontal dimensions and let performance be measured in
the vertical dimension.
The non-linearity of the relationships between the two
factors and overall performance leads to a rugged ‘per-
formance landscape’ with hills, ridges and valleys repre-
senting respectively better performance, knife-edge
performance and worse performance for particular com-
binations of the two factors [19]. Local optimization can
be represented as slow and steady progress up small
‘hills and ridges’, following the simple rule that ‘a little
further is better’. Clearly, this type of optimization can
lead to the system getting stuck at sub-optimal perform-
ance levels. Global optimization of would represent the
skipping of small hills, the traversing of deep valleys, on
the way to attaining the highest peak that represents op-
timal performance.
There is a trade-off between results and effort in
contrasting these two different types of optimization.
Local optimization is straightforward: for example, a
simple regression analysis will suggest that a factor is
significantly related to overall performance. However,
global optimization often requires advanced simulation
and modeling technology. Similar to other complex
domains, these approaches are indispensable in a clin-
ical context since the results of hypothesized changes
to multiple system components cannot be predicted
ahead of time and require in vitro experimentation.
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Consider the differences between traditional research
and applied research in, for example, improving the
quality of intensive care for cardiovascular disease. A
common clinical imperative is to measure and reduce
variability and improve end outcomes through process
standardization and improvement [20]. Classical use of
static regression-based models, no matter how detailed,
is unlikely to capture the complexity of cardiac surgery
processes or the interactions between providers and hos-
pitals [21]. Surveys and case studies may only isolate
some of the key success factors that allow hospital cath
labs to improve coronary intervention processes, [22]
and not be able to model all the interactions. These
methods are essentially all local optimization techniques,
familiar and easy to use. However, as local optimization
techniques, they are thus prone to missing potentially
far more significant improvement opportunities.
On the other hand, a holistic simulation approach,
using real-time data, could allow for safe experiential
learning and experimentation, and thus significant
improvements in the quality of such intensive care [23].
Coupled with multidisciplinary and trans disciplinary
teams, this less familiar and less widely used approach
would offer a more global optimization.
This trade-off between the ease of approach and po-
tential benefits may also partly underpin the well-known
phenomenon of the ‘flattening of the curve’ that repre-
sents US progress on health outcomes over time. Des-
pite continual advances in accumulated knowledge,
healthcare system performance often appears to have
reached a plateau in the US [24]. This is likely due to
the complex interplay between social determinants of
health such as education, knowledge, income, and loca-
tion [25]. To some degree, the ‘flattening’ of the value
curve is also likely also due to the medical epidemics of
diabetes, [26] obesity, [27] especially amongst the young.
We speculate, however, that the flattening of the per-
formance curve is partly also due to the delivery system’s
failure to adequately apply existing clinical knowledge,
or its application using local rather than global
optimization techniques.Increasing the application of scientific knowledge
Clinical medicine is becoming increasingly comfortable
with the use of technology to store patient data and
guide the provision of care [28]. A similar technology-
enabled shift towards deeper and more consistent appli-
cation of existing scientific knowledge is necessary.
While there is an emerging appreciation of the need for
different, [29] more systems-based research, [30] most
US federal funding for healthcare remains science-, and
not technology-based [9].To redress this, we believe, requires an unavoidable
change in funding priorities and a substantial increase in
the level of funding for technology development and the
application of existing scientific knowledge. Equally im-
portant is how such scarce funding resources are allo-
cated. Merely raising the proportion of NIH funding for
applied research or increasing AHRQ’s limited budget
will not suffice, especially if funding is generally limited
to projects involving the adoption of commercial off the
shelf based technologies such as electronic health
records.
To truly reap the returns on science-based research,
the increased funding for technology development must
also be better integrated with science-based research.
Adapting the mission orientation of the Department of
Defense, basic clinical science research must also include
technology transition plans. In this different paradigm,
research conducted ‘upstream’ with the objective of in-
creasing scientific knowledge must be held closer to ac-
count in terms of ‘downstream’ applications and
ultimately delivering mission-critical performance.
While our focus in this article is on the US health sys-
tem, it is noteworthy that other large healthcare systems
have wrestled with similar concerns and have implemen-
ted similar recommendations as ours. For example, in
the UK, the proportion of total funded research activity
accounted for by basic biomedical research was most re-
cently estimated as approximately two thirds of which
the majority was laboratory-based biomedical research
[31]. Another sixth of UK health research spending went
to treatment development and evaluation, which
includes applied and translational research.
In the Cooksey Report, Sir David Cooksey examined
publicly funded healthcare research and sought to pro-
vide recommendations to optimize its potential to bene-
fit patients, the National Health Servie and the wider
healthcare economy, on behalf of the UK Treasury. This
inquiry found that the UK risked failing to reap the full
economic, health and social benefits of the large invest-
ments being made by taxpayers into health research
[31].
In particular, the report diagnosed an absence of an
overarching strategy to translate ideas from basic and
clinical research into the development of new products
and approaches to treatment of disease and illness. Simi-
larly, another key gap noted was the absence of a strat-
egy to implement those new products and approaches
into clinical practice. Both gaps are ones we argue are
still present in the US healthcare system.
To a more limited extent the Report’s recommendations
on prioritizing projects in view of potential downstream
significance are also in line with our recommendation to
insist on an implementation plan for all basic research,
tying them more closely to applied research [31]. Beyond
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organizational changes in the delivery system and in the
research enterprise to better close the gaps between basic
and applied science, and theory and practice [31].
To a large extent, the degree of non-market control of
research and practice by centralized decision-makers is
arguably much stronger in the UK’s essentially nationa-
lized delivery system with centralized cost and compara-
tive effectiveness functions. We are not convinced that
changes to practice in the US will occur through
organizational and cultural changes alone. We believe
that demand-side consumer incentives and supply-side
payment reform as well as institutional innovation in the
markets for insurance and provision of care will be
required [32].
Summary
We remain convinced that system performance can im-
prove and that any real reductions of the returns to in-
vestment or innovation are still far off. This performance
deficit could, we argue, be addressed by implementing
and applying some of those half a million items of scien-
tific knowledge recently accumulated. This would be a
good start to improving the practice of medicine in the
US. These transformational improvements in the practice
of medicine could have positive impacts in other coun-
tries around the world as well, as dissemination of ap-
plied knowledge and innovations improves [33].
The next step is making sure that the next million
funded pieces of scientific research are also coupled to
technology applications to the fullest extent possible. It
bears repeating that only by applying the wealth of exist-
ing and future scientific knowledge can healthcare deliv-
ery and patient care ever improve.
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